{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T12:18:45Z","timestamp":1767010725346,"version":"3.48.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Peking Union Medical College Hospital Talent Cultivation Program","award":["UHB12554"],"award-info":[{"award-number":["UHB12554"]}]},{"name":"the National Natural Science Foundation of China under Grant","award":["82370041"],"award-info":[{"award-number":["82370041"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"DOI":"10.1007\/s12016-025-09118-2","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T12:15:46Z","timestamp":1767010546000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Efficacy of Combined and Standalone Oral Immunotherapies for Peanut Allergy: a Bayesian Network Meta-Analysis of RCTs"],"prefix":"10.1007","volume":"68","author":[{"given":"Xinyu","family":"Tian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisha","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"issue":"2","key":"9118_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-020-0898-7","volume":"20","author":"CM Warren","year":"2020","unstructured":"Warren CM, Jiang J, Gupta RS (2020) Epidemiology and burden of food allergy. Curr Allergy Asthma Rep 20(2):6. https:\/\/doi.org\/10.1007\/s11882-020-0898-7","journal-title":"Curr Allergy Asthma Rep"},{"key":"9118_CR2","doi-asserted-by":"crossref","unstructured":"Fleischer DM, Conover-Walker MK, Christie L, Burks AW, Wood RA (2003) The natural progression of peanut allergy: resolution and the possibility of recurrence. J Allergy Clin Immunol. 112(1):183\u201389. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12847497","DOI":"10.1067\/mai.2003.1517"},{"issue":"1","key":"9118_CR3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.mcna.2019.08.008","volume":"104","author":"M Mahdavinia","year":"2020","unstructured":"Mahdavinia M (2020) Food allergy in adults: presentations, evaluation, and treatment. Med Clin North Am 104(1):145\u201355. https:\/\/doi.org\/10.1016\/j.mcna.2019.08.008","journal-title":"Med Clin North Am"},{"key":"9118_CR4","unstructured":"Palforzia; cited 2025\u20135\u201317]. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/allergenics\/palforzia"},{"key":"9118_CR5","doi-asserted-by":"publisher","unstructured":"Vickery BP, Vereda A, Casale TB, Beyer K, du Toit G, Hourihane JO, et al. (2018) AR101 oral immunotherapy for peanut allergy. The New England Journal of Medicine. 379(21):1991\u20132001. https:\/\/doi.org\/10.1056\/NEJMoa1812856","DOI":"10.1056\/NEJMoa1812856"},{"issue":"6","key":"9118_CR6","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.anai.2019.02.006","volume":"122","author":"C Braun","year":"2019","unstructured":"Braun C, Caubet J (2019) Food oral immunotherapy is superior to food avoidance-CON. Ann Allergy Asthma Immunol 122(6):569\u2013571. https:\/\/doi.org\/10.1016\/j.anai.2019.02.006","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"8","key":"9118_CR7","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1111\/cea.13897","volume":"51","author":"A Fiocchi","year":"2021","unstructured":"Fiocchi A, Vickery BP, Wood RA (2021) The use of biologics in food allergy. Clin Exp Allergy 51(8):1006\u20131018. https:\/\/doi.org\/10.1111\/cea.13897","journal-title":"Clin Exp Allergy"},{"issue":"3","key":"9118_CR8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S2352-4642(22)00006-2","volume":"6","author":"P Loke","year":"2022","unstructured":"Loke P, Orsini F, Lozinsky AC, Gold M, O\u2019Sullivan MD, Quinn P et al (2022) Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial. Lancet Child Adolesc Health 6(3):171\u2013184. https:\/\/doi.org\/10.1016\/S2352-4642(22)00006-2","journal-title":"Lancet Child Adolesc Health"},{"key":"9118_CR9","doi-asserted-by":"publisher","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JPA, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clinical Research Ed.). 339:b2700. https:\/\/doi.org\/10.1136\/bmj.b2700","DOI":"10.1136\/bmj.b2700"},{"key":"9118_CR10","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ (Clinical Research Ed.). 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","DOI":"10.1136\/bmj.l4898"},{"issue":"1","key":"9118_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaci.2017.11.004","volume":"141","author":"AW Burks","year":"2018","unstructured":"Burks AW, Sampson HA, Plaut M, Lack G, Akdis CA (2018) Treatment for food allergy. J Allergy Clin Immunol 141(1):1. https:\/\/doi.org\/10.1016\/j.jaci.2017.11.004","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"9118_CR12","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/all.13319","volume":"73","author":"GB Pajno","year":"2018","unstructured":"Pajno GB, Fernandez-Rivas M, Arasi S, Roberts G, Akdis CA, Alvaro-Lozano M et al (2018) EAACI guidelines on allergen immunotherapy: IgE-mediated food allergy. Allergy 73(4):799\u2013815. https:\/\/doi.org\/10.1111\/all.13319","journal-title":"Allergy"},{"key":"9118_CR13","unstructured":"ICH e2a clinical safety data management: definitions and standards for expedited reporting - scientific guideline | european medicines agency (EMA); cited 2025\u20135\u201318]. Available from: https:\/\/www.ema.europa.eu\/en\/ich-e2a-clinical-safety-data-management-definitions-standards-expedited-reporting-scientific-guideline"},{"key":"9118_CR14","unstructured":"21 CFR 312.32 -- IND safety reporting.; cited 2025\u20135\u201318]. Available from: \/current\/title-21\/part-312\/section-312.32"},{"key":"9118_CR15","doi-asserted-by":"crossref","unstructured":"Sweeting MJ, Sutton AJ, Lambert PC (2004) What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 23(9):1351\u201375. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15116347","DOI":"10.1002\/sim.1761"},{"issue":"3","key":"9118_CR16","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2400306","volume":"4","author":"SH Sicherer","year":"2025","unstructured":"Sicherer SH, Bunyavanich S, Berin MC, Lo T, Groetch M, Schaible A et al (2025) Peanut oral immunotherapy in children with high-threshold peanut allergy. NEJM Evid 4(3):EVIDoa2400306. https:\/\/doi.org\/10.1056\/EVIDoa2400306","journal-title":"NEJM Evid"},{"issue":"5","key":"9118_CR17","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.jaip.2024.02.030","volume":"12","author":"C Uhl","year":"2024","unstructured":"Uhl C, Klevebro S, Sverremark-Ekstr\u00f6m E, Tedner SG, Brandstr\u00f6m J, Papageorgiou C et al (2024) High degree of desensitization after 1 year of early-life peanut oral immunotherapy: small children oral immunotherapy (SmaChO) randomized controlled trial. The Journal of Allergy and Clinical Immunology: In Practice 12(5):1297\u20131305. https:\/\/doi.org\/10.1016\/j.jaip.2024.02.030","journal-title":"The Journal of Allergy and Clinical Immunology: In Practice"},{"issue":"10","key":"9118_CR18","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1056\/NEJMoa2312382","volume":"390","author":"RA Wood","year":"2024","unstructured":"Wood RA, Togias A, Sicherer SH, Shreffler WG, Kim EH, Jones SM et al (2024) Omalizumab for the treatment of multiple food allergies. N Engl J Med 390(10):889\u2013899. https:\/\/doi.org\/10.1056\/NEJMoa2312382","journal-title":"N Engl J Med"},{"issue":"11","key":"9118_CR19","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2300145","volume":"2","author":"G Du Toit","year":"2023","unstructured":"Du Toit G, Brown KR, Vereda A, Irani A, Tilles S, Ratnayake A et al (2023) Oral immunotherapy for peanut allergy in children 1 to less than 4 years of age. NEJM Evid 2(11):EVIDoa2300145. https:\/\/doi.org\/10.1056\/EVIDoa2300145","journal-title":"NEJM Evid"},{"issue":"9","key":"9118_CR20","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1016\/j.jaip.2022.05.015","volume":"10","author":"DK Chu","year":"2022","unstructured":"Chu DK, Freitag T, Marrin A, Walker TD, Avilla E, Freitag A et al (2022) Peanut oral immunotherapy with or without h(1) and h(2) antihistamine premedication for peanut allergy (PISCES): a placebo-controlled randomized clinical trial. The Journal of Allergy and Clinical Immunology: In Practice 10(9):2386\u20132394. https:\/\/doi.org\/10.1016\/j.jaip.2022.05.015","journal-title":"The Journal of Allergy and Clinical Immunology: In Practice"},{"issue":"10322","key":"9118_CR21","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0140-6736(21)02390-4","volume":"399","author":"SM Jones","year":"2022","unstructured":"Jones SM, Kim EH, Nadeau KC, Nowak-Wegrzyn A, Wood RA, Sampson HA et al (2022) Efficacy and safety of oral immunotherapy in children aged 1\u20133 years with peanut allergy (the immune tolerance network IMPACT trial): a randomised placebo-controlled study. Lancet 399(10322):359\u2013371. https:\/\/doi.org\/10.1016\/S0140-6736(21)02390-4","journal-title":"Lancet"},{"issue":"10","key":"9118_CR22","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/S2352-4642(20)30234-0","volume":"4","author":"J O\u2019B Hourihane","year":"2020","unstructured":"O\u2019B Hourihane J, Beyer K, Abbas A, Fern\u00e1ndez-Rivas M, Turner PJ, Blumchen K et al (2020) Efficacy and safety of oral immunotherapy with AR101 in european children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial. Lancet Child Adolesc Health 4(10):728\u2013739. https:\/\/doi.org\/10.1016\/S2352-4642(20)30234-0","journal-title":"Lancet Child Adolesc Health"},{"issue":"10207","key":"9118_CR23","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/S0140-6736(19)31793-3","volume":"394","author":"RS Chinthrajah","year":"2019","unstructured":"Chinthrajah RS, Purington N, Andorf S, Long A, O\u2019Laughlin KL, Lyu SC et al (2019) Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study. Lancet 394(10207):1437\u20131449. https:\/\/doi.org\/10.1016\/S0140-6736(19)31793-3","journal-title":"Lancet"},{"key":"9118_CR24","doi-asserted-by":"publisher","unstructured":"Blumchen K, Trendelenburg V, Ahrens F, Gruebl A, Hamelmann E, Hansen G, et al. (2019) Efficacy, safety, and quality of life in a multicenter, randomized, placebo-controlled trial of low-dose peanut oral immunotherapy in children with peanut allergy. J Allergy Clin Immunol. In Practice. 7(2):479\u201391. https:\/\/doi.org\/10.1016\/j.jaip.2018.10.048","DOI":"10.1016\/j.jaip.2018.10.048"},{"key":"9118_CR25","doi-asserted-by":"publisher","unstructured":"Bird JA, Spergel JM, Jones SM, Rachid R, Assa'ad AH, Wang J, et al. (2018) Efficacy and safety of AR101 in oral immunotherapy for peanut allergy: results of ARC001, a randomized, double-blind, placebo-controlled phase 2 clinical trial. The Journal of Allergy and Clinical Immunology. In Practice. 6(2):476\u201385. https:\/\/doi.org\/10.1016\/j.jaip.2017.09.016","DOI":"10.1016\/j.jaip.2017.09.016"},{"issue":"2","key":"9118_CR26","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S2468-1253(17)30392-8","volume":"3","author":"S Andorf","year":"2018","unstructured":"Andorf S, Purington N, Block WM, Long AJ, Tupa D, Brittain E et al (2018) Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial. Lancet Gastroenterol Hepatol 3(2):85\u201394. https:\/\/doi.org\/10.1016\/S2468-1253(17)30392-8","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"9118_CR27","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/apa.13668","volume":"106","author":"AK Kukkonen","year":"2017","unstructured":"Kukkonen AK, Uotila R, Malmberg LP, Pelkonen AS, M\u00e4kel\u00e4 MJ (2017) Double-blind placebo-controlled challenge showed that peanut oral immunotherapy was effective for severe allergy without negative effects on airway inflammation. Acta Paediatrica (Oslo, Norway\u202f: 1992) 106(2):274\u2013281. https:\/\/doi.org\/10.1111\/apa.13668","journal-title":"Acta Paediatrica (Oslo, Norway : 1992)"},{"key":"9118_CR28","doi-asserted-by":"publisher","unstructured":"MacGinnitie AJ, Rachid R, Gragg H, Little SV, Lakin P, Cianferoni A, et al. (2017) Omalizumab facilitates rapid oral desensitization for peanut allergy. The Journal of Allergy and Clinical Immunology 139(3):873\u201381. https:\/\/doi.org\/10.1016\/j.jaci.2016.08.010","DOI":"10.1016\/j.jaci.2016.08.010"},{"key":"9118_CR29","doi-asserted-by":"publisher","unstructured":"Tang MLK, Ponsonby A, Orsini F, Tey D, Robinson M, Su EL, et al. (2015) Administration of a probiotic with peanut oral immunotherapy: a randomized trial. J Allergy Clin Immunol 135(3):737\u201344. https:\/\/doi.org\/10.1016\/j.jaci.2014.11.034","DOI":"10.1016\/j.jaci.2014.11.034"},{"issue":"9925","key":"9118_CR30","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/S0140-6736(13)62301-6","volume":"383","author":"K Anagnostou","year":"2014","unstructured":"Anagnostou K, Islam S, King Y, Foley L, Pasea L, Bond S et al (2014) Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial. Lancet 383(9925):1297\u20131304. https:\/\/doi.org\/10.1016\/S0140-6736(13)62301-6","journal-title":"Lancet"},{"issue":"3","key":"9118_CR31","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.jaci.2010.12.1111","volume":"127","author":"P Varshney","year":"2011","unstructured":"Varshney P, Jones SM, Scurlock AM, Perry TT, Kemper A, Steele P et al (2011) A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol 127(3):654\u2013660. https:\/\/doi.org\/10.1016\/j.jaci.2010.12.1111","journal-title":"J Allergy Clin Immunol"},{"key":"9118_CR32","doi-asserted-by":"publisher","unstructured":"Sampson HA, Leung DYM, Burks AW, Lack G, Bahna SL, Jones SM, et al. (2011) A phase II, randomized, double\u2011blind, parallel\u2011group, placebo\u2011controlled oral food challenge trial of xolair (omalizumab) in peanut allergy 1309\u201310. https:\/\/doi.org\/10.1016\/j.jaci.2011.01.051","DOI":"10.1016\/j.jaci.2011.01.051"},{"key":"9118_CR33","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical Research Ed.) 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"issue":"7\u20138","key":"9118_CR34","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/sim.3767","volume":"29","author":"S Dias","year":"2010","unstructured":"Dias S, Welton NJ, Caldwell DM, Ades AE (2010) Checking consistency in mixed treatment comparison meta-analysis. Stat Med 29(7\u20138):932\u2013944. https:\/\/doi.org\/10.1002\/sim.3767","journal-title":"Stat Med"},{"issue":"1","key":"9118_CR35","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.1167","volume":"7","author":"G van Valkenhoef","year":"2016","unstructured":"van Valkenhoef G, Dias S, Ades AE, Welton NJ (2016) Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis. Res Synth Methods 7(1):80\u201393. https:\/\/doi.org\/10.1002\/jrsm.1167","journal-title":"Res Synth Methods"},{"key":"9118_CR36","unstructured":"USDA national nutrient database for standard reference, legacy release; cited 2025\u20135\u201320]. Available from: \/articles\/dataset\/USDA_National_Nutrient_Database_for_Standard_Reference_Legacy_Release\/24661818\/1"},{"issue":"1","key":"9118_CR37","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s11882-012-0316-x","volume":"13","author":"JA Lieberman","year":"2013","unstructured":"Lieberman JA, Chehade M (2013) Use of omalizumab in the treatment of food allergy and anaphylaxis. Curr Allergy Asthma Rep 13(1):78\u201384. https:\/\/doi.org\/10.1007\/s11882-012-0316-x","journal-title":"Curr Allergy Asthma Rep"},{"issue":"1","key":"9118_CR38","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.anai.2023.04.023","volume":"131","author":"SB Sindher","year":"2023","unstructured":"Sindher SB, Hillier C, Anderson B, Long A, Chinthrajah RS (2023) Treatment of food allergy: oral immunotherapy, biologics, and beyond. Annals of Allergy, Asthma & Immunology: Official Publication of the American 131(1):29\u201336. https:\/\/doi.org\/10.1016\/j.anai.2023.04.023","journal-title":"Annals of Allergy, Asthma & Immunology: Official Publication of the American"},{"key":"9118_CR39","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00751-2020","author":"J L\u00f3pez-Abente","year":"2021","unstructured":"L\u00f3pez-Abente J, Benito-Villalvilla C, Jaumont X, Pfister P, Tassinari P, Palomares O (2021) Omalizumab restores the ability of human plasmacytoid dendritic cells to induce foxp3(+)tregs. Eur Respir J. https:\/\/doi.org\/10.1183\/13993003.00751-2020","journal-title":"Eur Respir J"},{"issue":"8","key":"9118_CR40","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/gene.2014.45","volume":"15","author":"O Palomares","year":"2014","unstructured":"Palomares O, Mart\u00edn-Fontecha M, Lauener R, Traidl-Hoffmann C, Cavkaytar O, Akdis M et al (2014) Regulatory t cells and immune regulation of allergic diseases: roles of IL-10 and TGF-\u03b2. Genes Immun 15(8):511\u2013520. https:\/\/doi.org\/10.1038\/gene.2014.45","journal-title":"Genes Immun"},{"key":"9118_CR41","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.12650.1","volume":"7","author":"A Abdel-Gadir","year":"2018","unstructured":"Abdel-Gadir A, Massoud AH, Chatila TA (2018) Antigen-specific treg cells in immunological tolerance: implications for allergic diseases. F1000Res 7:38. https:\/\/doi.org\/10.12688\/f1000research.12650.1","journal-title":"F1000Res"},{"key":"9118_CR42","doi-asserted-by":"publisher","unstructured":"Burks AW, Calderon MA, Casale T, Cox L, Demoly P, Jutel M, et al. (2013) Update on allergy immunotherapy: american academy of allergy, asthma & immunology\/european academy of allergy and clinical immunology\/PRACTALL consensus report. J Allergy Clin Immunol 131(5):1288\u201396. https:\/\/doi.org\/10.1016\/j.jaci.2013.01.049","DOI":"10.1016\/j.jaci.2013.01.049"},{"issue":"4","key":"9118_CR43","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/cea.13824","volume":"51","author":"SM Barshow","year":"2021","unstructured":"Barshow SM, Kulis MD, Burks AW, Kim EH (2021) Mechanisms of oral immunotherapy. Clin Exp Allergy 51(4):527\u2013535. https:\/\/doi.org\/10.1111\/cea.13824","journal-title":"Clin Exp Allergy"},{"issue":"3","key":"9118_CR44","doi-asserted-by":"publisher","first-page":"151","DOI":"10.18176\/jiaci.0143","volume":"27","author":"RA Wood","year":"2017","unstructured":"Wood RA (2017) Oral immunotherapy for food allergy. J Investig Allergol Clin Immunol 27(3):151\u2013159. https:\/\/doi.org\/10.18176\/jiaci.0143","journal-title":"J Investig Allergol Clin Immunol"},{"key":"9118_CR45","doi-asserted-by":"publisher","unstructured":"Jones SM, Pons L, Roberts JL, Scurlock AM, Perry TT, Kulis M, et al. (2009) Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol. 124(2):292\u2013300, 300\u201301. https:\/\/doi.org\/10.1016\/j.jaci.2009.05.022","DOI":"10.1016\/j.jaci.2009.05.022"},{"key":"9118_CR46","doi-asserted-by":"publisher","unstructured":"Patil SU, Ogunniyi AO, Calatroni A, Tadigotla VR, Ruiter B, Ma A, et al. (2015) Peanut oral immunotherapy transiently expands circulating ara h 2-specific b cells with a homologous repertoire in unrelated subjects. The Journal of Allergy and Clinical Immunology 136(1):125\u201334. https:\/\/doi.org\/10.1016\/j.jaci.2015.03.026","DOI":"10.1016\/j.jaci.2015.03.026"},{"issue":"18","key":"9118_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/nu15184014","volume":"15","author":"V Notarbartolo","year":"2023","unstructured":"Notarbartolo V, Carta M, Accomando S, Giuffr\u00e8 M (2023) The first 1000 days of life: how changes in the microbiota can influence food allergy onset in children. Nutrients 15(18):4014. https:\/\/doi.org\/10.3390\/nu15184014","journal-title":"Nutrients"},{"issue":"24","key":"9118_CR48","doi-asserted-by":"publisher","first-page":"10784","DOI":"10.1039\/d3fo03321j","volume":"14","author":"J Shi","year":"2023","unstructured":"Shi J, Dong P, Liu C, Xu Y, Zheng M, Cheng L et al (2023) Lactobacillus rhamnosus probio-m9 alleviates OVA-sensitized food allergy through modulating gut microbiota and its metabolism. Food Funct 14(24):10784\u201310795. https:\/\/doi.org\/10.1039\/d3fo03321j","journal-title":"Food Funct"},{"key":"9118_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00996","volume":"11","author":"K Pratap","year":"2020","unstructured":"Pratap K, Taki AC, Johnston EB, Lopata AL, Kamath SD (2020) A comprehensive review on natural bioactive compounds and probiotics as potential therapeutics in food allergy treatment. Front Immunol 11:996. https:\/\/doi.org\/10.3389\/fimmu.2020.00996","journal-title":"Front Immunol"},{"issue":"2","key":"9118_CR50","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.alit.2020.01.004","volume":"69","author":"Y Okayama","year":"2020","unstructured":"Okayama Y, Matsumoto H, Odajima H, Takahagi S, Hide M, Okubo K (2020) Roles of omalizumab in various allergic diseases. Allergol Int 69(2):167\u2013177. https:\/\/doi.org\/10.1016\/j.alit.2020.01.004","journal-title":"Allergol Int"},{"issue":"4","key":"9118_CR51","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.jaip.2022.11.036","volume":"11","author":"T Zuberbier","year":"2023","unstructured":"Zuberbier T, Wood RA, Bindslev-Jensen C, Fiocchi A, Chinthrajah RS, Worm M et al (2023) Omalizumab in IgE-mediated food allergy: a systematic review and meta-analysis. The Journal of Allergy and Clinical Immunology: In Practice 11(4):1134\u20131146. https:\/\/doi.org\/10.1016\/j.jaip.2022.11.036","journal-title":"The Journal of Allergy and Clinical Immunology: In Practice"},{"issue":"8","key":"9118_CR52","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1111\/all.16129","volume":"79","author":"C Riggioni","year":"2024","unstructured":"Riggioni C, Oton T, Carmona L, Du Toit G, Skypala I, Santos AF (2024) Immunotherapy and biologics in the management of IgE-mediated food allergy: systematic review and meta-analyses of efficacy and safety. Allergy 79(8):2097\u20132127. https:\/\/doi.org\/10.1111\/all.16129","journal-title":"Allergy"},{"issue":"4","key":"9118_CR53","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/alr.23268","volume":"14","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Zhang M, Zhang J, Li Q, Lu M, Cheng L (2024) Combination of omalizumab with allergen immunotherapy versus immunotherapy alone for allergic diseases: a meta-analysis of randomized controlled trials. Int Forum Allergy Rhinol 14(4):794\u2013806. https:\/\/doi.org\/10.1002\/alr.23268","journal-title":"Int Forum Allergy Rhinol"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-025-09118-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-025-09118-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-025-09118-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T12:15:47Z","timestamp":1767010547000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-025-09118-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9118"],"URL":"https:\/\/doi.org\/10.1007\/s12016-025-09118-2","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"14 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not required for this study, as it is a network meta-analysis based on previously published data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"113"}}